Investing Profile

Robert Nelsen

VCInvestorAngel
Co-founder and a Managing Director of ARCH Venture Partners
Photo of Robert Nelsen, Managing Director at ARCH Venture Partners

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
ARCH Venture Partners Managing Director
$50K - $150.0M
$75.0M
92
$635.8M
CompanyStageDateRound SizeTotal Raised
Dispatch Bio
Series AJul 2025$220M
$220M
Co-investors: Steven Gillis (ARCH Venture Partners)
Be Biopharma
Series CJan 2025$92M
Series UnknownOct 2024$82M
Series BApr 2022$130M
$360M
Co-investors: Steven Gillis (ARCH Venture Partners), Jason Rhodes (Atlas Venture), Melissa McCracken (Nextech Invest)
City Therapeutics
Series AOct 2024$140M
$140M
Co-investors: Ari Nowacek (ARCH Venture Partners)
Stability AI
Series UnknownJun 2024$80M
$210M
£89M
Co-investors: Colin Bryant (New Enterprise Associates (NEA)), Gaurav Gupta (Lightspeed Venture Partners), Effie Epstein (Sound Ventures), Guy Oseary (Sound Ventures), Ashton Kutcher (Sound Ventures), Chris Denny-Brown (O'Shaughnessy Ventures), Dana Settle (Greycroft), Walter Kortschak (Summit Partners), Jim O'Shaughnessy (O'Shaughnessy Ventures), Eric Schmidt (Innovation Endeavors), Mei Z.
Vilya
Series AJun 2024$21M
Series AAug 2022$50M
$71M
Co-investors: Greg Yap (Menlo Ventures), Steven Gillis (ARCH Venture Partners)
Gameto
Series BMay 2024$33M
Series AJan 2022$20M
$120M
Co-investors: Dan Rose (Coatue), Dylan Morris (Insight Partners), Steve Jurvetson (Future Ventures), Maryanna Saenko (Future Ventures), Dusan Perovic (Two Sigma Ventures), Laura Stoppel (RA Capital), Jack Abraham (Atomic), Peter Kolchinsky (RA Capital), Anne Wojcicki
Xaira Therapeutics
Series AApr 2024$1B
$1B
Co-investors: Scott Gottlieb (New Enterprise Associates (NEA)), Vikram Bajaj (Foresite Capital)
Seaport Therapeutics
Series AApr 2024$100M
$330M
Co-investors: Brett Zbar (General Atlantic), James Healy (Sofinnova Investments)